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Tumor-associated peptide–human leukocyte antigen complexes (pHLAs) represent the largest pool of cell surface–
expressed cancer-specific epitopes, making them attractive targets for cancer therapies. Soluble bispecific molecules that
incorporate an anti-CD3 effector function are being developed to redirect T cells against these targets using 2 different
approaches. The first achieves pHLA recognition via affinity-enhanced versions of natural TCRs (e.g., immune-mobilizing
monoclonal T cell receptors against cancer [ImmTAC] molecules), whereas the second harnesses an antibody-based
format (TCR-mimic antibodies). For both classes of reagent, target specificity is vital, considering the vast universe of
potential pHLA molecules that can be presented on healthy cells. Here, we made use of structural, biochemical, and
computational approaches to investigate the molecular rules underpinning the reactivity patterns of pHLA-targeting
bispecifics. We demonstrate that affinity-enhanced TCRs engage pHLA using a comparatively broad and balanced
energetic footprint, with interactions distributed over several HLA and peptide side chains. As ImmTAC molecules, these
TCRs also retained a greater degree of pHLA selectivity, with less off-target activity in cellular assays. Conversely, TCR-
mimic antibodies tended to exhibit binding modes focused more toward hot spots on the HLA surface and exhibited a
greater degree of crossreactivity. Our findings extend our understanding of the basic principles that underpin pHLA
selectivity and exemplify a number of molecular approaches that can be used to probe the specificity of pHLA-targeting
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Introduction
The ability to selectively target tumor-specific antigens holds 
great promise for the development of specific cancer treat-
ments, but their identification remains a key challenge. Pep-
tide fragments presented on the cell surface by human leuko-
cyte antigens (pHLAs) represent the intracellular proteome, 
and because this also includes dysregulated and cancer- 
specific proteins (1, 2), pHLAs constitute an important source 
of tumor-specific antigens. However, targeting these molecules 
is difficult for 2 reasons. First, their natural presentation levels 
can be very low (often below 10 copies of each specific peptide 
epitope per cell) (3); and second, peptides are corecognized in 
the context of HLA, a molecule expressed by most cells (i.e., 
peptide selectivity could be lost if HLA interactions dominate 
the binding interface) (4, 5).
The immune system naturally overcomes these hurdles via 
selective T cell receptor (TCR) recognition of pHLA, enabling T 
cell triggering toward low-level antigens (6–8). Although the mech-
anisms that determine peptide selectivity by natural TCRs are not 
fully understood, the binding mode employed by the TCR is likely 
to be fundamentally important, as evidenced by the conserved 
binding mode observed for virtually all TCR-pHLA structures 
solved to date (9). This canonical interaction places the TCR diag-
onally across the HLA-binding groove, positioning the somatically 
rearranged TCR complementarity determining region 3 (CDR3) 
loops centrally over the antigenic determinant (peptide) with the 
germline-encoded CDR1/2 loops positioned primarily over the 
HLA helices, enabling natural TCRs to detect pHLA in a peptide- 
dependent manner. Despite the need for precise peptide selectivity, 
a limited number of TCRs must still maintain the ability to recognize 
millions of potential target antigens (10, 11). Consequently, TCRs 
have been shown to crossreact with a vast array of different peptides 
(11–14), but are selected in the thymus to avoid having specificities 
overlapping with abundant self-epitopes to maintain self-tolerance. 
Although the mechanisms that underpin these characteristics have 
yet to be determined, the relatively weak binding affinity of thymi-
cally selected TCRs (KDs in the micromolar affinity range; refs. 15, 
16) has been shown to be important for T cell sensitivity (17) and is 
likely also important for maintaining self-tolerance.
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Results
Structural analysis of pHLA-targeting reagents. We selected 
TCR-mimic antibodies according to in vitro and in vivo testing 
and based on the availability of crystal complex structures to 
enable molecular analysis (Supplemental Table 1; supplemental 
material available online with this article; https://doi.org/10.1172/
JCI130562DS1). Several additional TCR mimics have been report-
ed; however, most lacked sufficient published information for 
inclusion (sequence, structure, and specificity data). As the pep-
tide antigen can have a major influence on specificity (i.e., some 
peptides may have close homology to self-peptides), we chose 
affinity-enhanced TCRs based on their recognition of identi-
cal, or closely related, pHLA determinants compared with the 
TCR mimics. Here, we assessed reagents designed to recognize 
the NY-ESO-1157–165 cancer testis antigen–derived peptide SLLM-
WITQC, presented by HLA-A*02:01 (A2-SLL), the MAGE-A1161–169/
MAGE3-A3168–176 melanoma-associated antigen-derived peptides 
EADPTGHSY (A1-EAD) and EVDPIGHLY (A1-EVD), presented 
by HLA-A*01:01, and the WT126–134 Wilms tumor antigen–derived 
peptide RMFPNAPYL, presented by HLA-A*02:01 (A2-RMF). 
Although not a direct comparison, the A1-EAD and A1-EVD still 
represented a useful system to include due to the similar tumor- 
expression patterns of both proteins, the same HLA restriction, 
and similar peptide sequences — a consequence of both peptides 
representing the same region of the highly related MAGE proteins.
In addition to the previously published crystal structures for 
TCR-mimic antibodies and affinity-enhanced TCRs in complex 
with A2-SLL (36, 44, 45), A2-RMF (25), and A1-EVD/A1-EAD 
(refs. 46, 47, and Figure 1A), we solved the structure of the affinity- 
enhanced WT1_α7β2 TCR in complex with A2-RMF at 2.8 Å to 
complete the set (Table 1). Together, these data were analyzed to 
identify any structural features that might influence the peptide 
selectivity of each reagent. We compared the normal range of 
binding (crossing angle and engagement zone) of natural TCRs 
(9) with both affinity-enhanced TCRs and TCR-mimic antibod-
ies. The affinity-enhanced TCRs (1G4_α58β61 TCR, MAG-IC3 
TCR, and WT1_α7β2 TCR) bound within the normal range of nat-
ural TCR topologies, with the CDR3 loops of both chains focused 
over the central peptide bulge (amino acids 4–6) (Figure 1B). 
This binding mode enabled the affinity-enhanced TCRs to form 
contacts with 5 of the 9 amino acids in the peptide and multiple 
interactions with the α1 and α2 domains of the HLA (Table 2). The 
1G4_α58β61 and WT1_α7β2 TCRs were more peptide focused than 
the MAG-IC3 TCRs in terms of the percentages (57%, 36%, and 
14%, respectively) and numbers (115, 64, and 16, respectively) of 
peptide bonds. The 1G4_α58β61 and WT1_α7β2 TCRs also exhibited 
larger buried surface areas (BSAs) than MAG-IC3, but all were 
within, or near to, the normal range (1240–2400 Å2) (9). The 
3M4E5 TCR-mimic antibody bound in a fashion very similar to 
that of natural TCRs, making contacts with 5 peptide residues, 
38% peptide contacts, and a BSA of 2502 Å2. However, the struc-
tural analysis revealed focusing of interactions at peptide residue 
W5, where half of the peptide contacts were concentrated (24/51). 
Although the 1G4_α58β61 TCR also made many contacts with the 
large exposed side chain of W5 (54/115), binding was less focused 
on this residue and additional important contacts were made with 
other peptide residues, particularly M4 (31/115) and Q8 (15/115). 
The weak affinity of naturally selected TCRs, combined 
with difficulties manufacturing a membrane-bound protein as 
a soluble reagent, imposes certain challenges on their use for 
therapeutic applications. Consequently, the most widely used 
T cell–based therapies involve the adoptive transfer of either 
expanded antigen-specific T cells or T cells genetically modified 
to express an artificial antigen-specific TCR (specific peptide 
affinity-enhanced receptor [SPEAR]) (18) or antibody (chimeric 
antigen receptor [CAR]) (19). Although promising, these thera-
pies are complicated by the need to prepare therapeutic T cells 
on a patient-by-patient basis and an inability to control dosing in 
response to potential toxicities (20).
Soluble bispecific T cell redirectors, consisting of antigen rec-
ognition and T cell–engaging domains, bypass many of the lim-
itations of the adoptive transfer approach (21). The antigen recog-
nition of pHLA-targeting reagents may be via a TCR or antibody 
domain. Immune-mobilizing monoclonal T cell receptors against 
cancer (ImmTAC) molecules are bispecific molecules with an 
engineered soluble TCR fused to an anti-CD3 effector function 
(22); thus, these molecules redirect T cells specifically toward cells 
presenting a target pHLA (22). The TCR component of ImmTAC 
molecules is stabilized with an interchain disulphide bond (23) 
and affinity enhanced using phage display to generate highly sta-
ble, soluble TCR reagents that can bind to pHLA with low-picomo-
lar affinities and with binding half-lives of several hours (in com-
parison with half-lives of seconds for WT soluble TCRs) (22, 24). 
These attributes enable ImmTAC molecules to elicit antitumor 
responses at picomolar concentrations against cells expressing 
very low levels of pHLA on the cell surface. In comparison, bispe-
cific T cell engagers (BiTEs) can utilize antibodies to target pHLA 
(TCR-mimic antibodies) as soluble T cell–engaging bispecific 
molecules (25–38). Antibodies, unlike TCRs that are anchored in 
the cell membrane, can exist naturally as soluble effector mole-
cules (and as such, are easier to engineer as soluble reagents) 
and typically have a strong affinity for their antigen (nanomolar 
range), making them attractive for development as soluble thera-
peutics (21). The main challenge for a targeted pHLA therapeutic 
is achieving sufficient specificity in the context of a vast landscape 
of potential self-antigens. For instance, even on individual cell 
types, data from our in-house mass spectrometry database and 
published direct evidence demonstrate that the number of unique 
peptides can be in the range of tens of thousands (39–42). Con-
sidering the full human protein-coding genome, the number of 
peptides presented has been estimated to be over 11 million (43).
In this study, we used a combination of structural, molecu-
lar, and computational approaches to understand the molecular 
mechanisms underpinning pHLA selectivity and, consequently, 
the potential crossreactivity of soluble bispecific T cell redirectors. 
We demonstrate that utilization of a native TCR-like binding mode 
was not predictive of peptide selectivity. In fact, peptide selectivi-
ty, as defined by lower levels of pHLA crossreactivity and less off- 
target activity in cellular testing, was associated with an energetic 
signature characterized by broad interactions with several peptide 
side chains as well as the peptide backbone. These findings have 
important implications for the underlying rules that determine 
pHLA discrimination and identify key considerations in the design 
of immunotherapeutics that target these cell-surface proteins.
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each peptide residue was replaced with an alanine (or a serine if 
the native residue was already an alanine), except for the canoni-
cal anchor residues at positions 2 and 9. The 1G4_α58β61 TCR bound 
to A2-SLL with a KD = 57 pM. However, binding was not detected 
when residues 5 and 6 were mutated to alanine, and the affinity 
was substantially reduced when residues 4, 7, and 8 were mutated 
(Figure 2A). These findings are consistent with the 1G4_α58β61-
A2-SLL cocomplex crystal structure showing that the central MW 
motif forms a central peptide bulge, making multiple contacts 
with the TCR CDR3 loops, and peptide residue Q8 points up away 
from the HLA surface, enabling contacts with the TCR CDR1β 
loop (Figure 1 and Table 2). A similar pattern was observed for the 
1G4_α5β51 A2-SLL restricted TCR (a different affinity mutant ver-
sion of 1G4_α58β61 originating from the same progenitor WT TCR, 
KD = 1.4 nM), with reductions in affinity additionally observed 
at peptide positions 1 and 3, whereas the 1G4_α5β100 A2-SLL 
restricted TCR (a different affinity mutant version of 1G4_α58β61 
originating from the same progenitor WT TCR), which bound 
with a weaker affinity (KD = 5 nM), was highly sensitive to alanine 
mutations at every position along the peptide backbone (Fig-
ure 2A). We repeated the alanine scan analysis on the A2-SLL– 
reactive 3M4E5 TCR mimic and included 2 published higher affin-
ity versions of 3M4E5 (36) (3M4E5_T2 and 3M4E5_T3) because 
they were closer in affinity to the 1G4_α5β100 and 1G4_α5β51 affinity- 
enhanced TCRs, allowing a more direct comparison. The 3M4E5 
(KD = 44 nM in single-chain fusion [scFv] format) and 3M4E5_T2 
TCR-mimic antibodies (KD = 2.8 nM in scFv format) were both 
Peptide-binding hot spots have been detected for natural TCRs 
(12, 48, 49); however, this structural feature has been associated 
with autoreactive TCRs and can correlate with a high level of TCR 
crossreactivity (14, 49). In contrast, the Hyb3.3 and ESK-1–mimic 
antibodies both bound to their respective pHLA using unconven-
tional topology. Hyb3.3 binding was C-terminally shifted with a 
crossing angle substantially outside of the natural TCR-pHLA 
range. Despite this unusual topology, Hyb3.3 retained broad pep-
tide contacts across 6 of the 9 amino acids, making 25% peptide 
contacts and a BSA of 2024 Å2 (Table 2). ESK-1 binding was N- 
terminally shifted with an unconventional crossing angle. This 
binding mode positioned the TCR-mimic antibody so that the 
CDR3 loops were focused over the α2 helix of the HLA, resulting 
in a very limited interaction with the peptide. This binding mode 
resulted in ESK-1 making only 10% peptide contacts, and the major-
ity of these were formed with peptide residue 1. This HLA-centric 
binding mode, where only 1 peptide residue was contacted, raised 
questions about the ability of the ESK-1 TCR mimic to retain spec-
ificity. However, for all the other HLA-targeting reagents consid-
ered here, their structures appeared to retain many of the features 
observed for natural TCR-pHLA interactions.
Alanine scan analysis reveals distinct molecular recognition pat-
terns between TCRs and TCR-mimic antibodies. Alanine scan muta-
genesis was used to investigate the molecular recognition pattern 
of the affinity-enhanced TCRs and TCR-mimic antibodies using 
surface plasmon resonance (Figure 2 and Supplemental Figure 1). 
For each reagent, we generated a panel of soluble pHLAs in which 
Figure 1. Structural analysis of pHLA-targeting reagents. Structures of the TCRs and TCR mimics, in complex with pHLA, were analyzed to determine the 
structural mechanism underpinning their binding characteristics. (A) TCRs (blue ribbon) or TCR mimics (orange ribbon) binding to peptide (red sticks) and 
HLA (green ribbon) compared with the binding range employed by all published WT TCR structures (gray drawing). Yellow arrows indicate unconventional 
binding modes. (B) Colors are as in A. Top down view of TCR or TCR mimic binding to pHLA. Black circles represent the center of binding. Yellow arrows 
indicate unconventional binding modes.
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protein (MAGE-A1), and binds with an affinity of KD = 18 nM. The 
MAGE-A3 and MAGE-A1 peptides are conserved at all positions 
except for the N-terminal anchor (position 2), position 5, and posi-
tion 8. Although the Hyb3.3-A1-EAD complex structure demon-
strated noncanonical topology, the interactions with the peptide 
apparent in the structure were comparable to most TCR-pHLA 
complexes (Figure 1 and Table 2). This observation was reflected 
in the alanine scan analysis, which demonstrated some degree 
of sensitivity to alanine substitutions at all positions tested apart 
from peptide residue 1 (Figure 2D).
The WT1_α7β2 TCR, which bound A2-RMF with a KD = 70 
nM, exhibited abrogated or highly reduced binding for all res-
idues except at peptide position 6. The WT1_α27β2 (KD = 13 nM) 
and WT1_α42β2 (KD = 0.76 nM) TCRs (both different affinity 
mutant versions of WT1_α7β2 TCR originating from the same 
progenitor WT TCR) showed a similar trend, with the strongest 
binding WT1_α42β2 TCR exhibiting the greatest level of sensitiv-
ity to alanine substitutions across the peptide backbone (Fig-
ure 2E). The ESK1 TCR-mimic antibody, which has a relatively 
weak affinity for A2-RMF of KD = 2 μM in scFv format (Supple-
mental Figure 1), demonstrated broad degeneracy in peptide 
binding, being tolerant to alanine substitutions at all positions 
of the peptide except for peptide residue 1 (Figure 2F). Here, 
availability of the ESK-1-A2-WT-1 structure provided insight 
into this observation, confirming that virtually all contacts 
between ESK-1 and the WT-1 peptide were focused on peptide 
residue 1 (Figure 1 and Table 2).
TCR-mimic antibodies bind to several commonly expressed 
self-peptides. Although alanine scan analysis is useful for under-
standing positional sensitivity of pHLA-targeting receptors, it 
is unclear how these data relate to the broader crossreactivity of 
these reagents, particularly their ability to discriminate against 
common self-peptides. To gain further insight into self-discrimi-
nation, we designed an experimental approach for screening mul-
tiple pHLA complexes in a high-throughput format by modifying 
the MagPix platform. We designed multiplex experiments using 
MagPlex beads coated with HLAs in complex with a range of com-
monly expressed self-peptides. Self-peptide HLAs recognized by 
affinity-enhanced TCRs or TCR mimics were detected using Mag-
Pix analysis (Tables 3 and 4). In all cases, the affinity-enhanced 
TCR reagents only generated a signal against their respective 
index peptides, whereas the TCR-mimic antibodies (in scFv for-
mat to avoid avidity-mediated binding) were more promiscuous. 
The 3M4E5_T2 scFv was reactive against 4 broadly expressed 
HLA-A*02:01 restricted self-peptides, and the ESK1 scFv demon-
strated reactivity against 6 broadly expressed HLA-A*02:01 
restricted self-peptides, in addition to their target antigens A2-SLL 
and A2-RMF, respectively (Table 3). The Hyb3.3 scFv was reactive 
against almost all of the HLA-A*01:01 restricted self-peptides 
tested (9/12) as well as A1-EAD (Table 4). In all cases, the self- 
peptides recognized by the TCR-mimic antibodies shared very 
little sequence similarity, revealing a high level of potential cross-
reactivity compared with the affinity-enhanced TCRs developed 
to target identical, or very similar, peptide antigens.
Deep sequencing of peptides from randomized pHLA phage 
libraries demonstrates the binding degeneracy of pHLA-targeting 
reagents. Despite the ability of 3M4E5 to bind pHLA in a TCR-
sensitive to alanine mutation at peptide residues 4, 5, and 6 (Fig-
ure 2B), whereas mutations at all other positions of the peptide 
did not reduce binding affinity. 3M4E5_T3 (KD = 5.5 nM in scFv 
format) demonstrated a similar trend, being sensitive to alanine 
substitution at peptide residues 4 and 5 (Figure 2B). Alanine sub-
stitutions at peptide residues 1, 3, 7, and 8 had no impact on bind-
ing affinity for any of the A2-SLL TCR mimics, demonstrating a 
more focused binding mode around peptide residues 4, 5, and 6 
compared with the affinity-enhanced TCRs. These findings were 
also consistent with the crystal structure of 3M4E5-A2-SLL that 
demonstrated binding was focused toward these central residues 
of the peptide.
The high level of sensitivity to alanine substitutions across 
the peptide backbone was also observed for the A1-EVD–specific 
MAG-IC3 (KD = 3.8 nM) and MAG-IC5 (a different affinity mutant 
version of MAG-IC3 TCR originating from the same progeni-
tor WT TCR, KD = 17 nM) TCRs (Figure 2C). The stronger affin-
ity MAG-IC3 TCR demonstrated reduced or abrogated affinity 
toward every alanine mutant tested, while the MAG-IC5 TCR was 
sensitive to mutations at all positions apart from peptide residues 
6 and 7. The MAG-IC3-A1-EVD cocomplex crystal structure was 
consistent with this finding, demonstrating a complex network of 
contacts across the peptide backbone (Figure 1 and Table 2). The 
Hyb3.3 TCR-mimic antibody recognizes the same peptide region 
as MAG-IC3 and MAG-IC5, but derived from a different MAGE 
Table 1. Data collection and refinement statistics for WT1_α7β2-
A2-RMF and NYBR1-A2-SLS structures
WT1_α7β2-A2-RMF NYBR1-A2-SLS
PDB code 6RSY 6R2L
AData collection  
Space group P 21 21 21 P 1 21 1
Cell dimensions  
 a, b, c (Å) 94.6, 114.8, 185.4 52.2, 99.3, 111.4
 α, β, γ (°) 90, 90, 90 90, 90.5, 90
Resolution (Å) 114.8-.03B (3.0-3.0) 52.2-2.4B (2.4-2.3)
Beam line I04–1 I04–1
Beam time code In17077-18 14843-1
Rmerge (%) 32.6 
B(220.4) 20.7 B(108.9)
I/σI 8.8 B(1.2) 9.7 B(1.3)
Completeness (%) 99.9 B(99.9) 99.7 B(99.7)
Redundancy 14.1 B(14.3) 3.7 B(3.6)
No. reflections 700,229 B(54,486) 188,042 B(13,553)
Refinement  
No Rfree reflections 2,370 2,435
Rwork / Rfree 25.1/29.1 21.4/26.5
R.m.s. deviations  
Bond lengths (Å) 0.006 0.011
Bond Angles (°) 1.253 1.853
Mean B value (Å2) 75.5 40.0
Wilson B factor (Å2) 75.8 25.9
Estimated coordinate error based 
on maximum likelihood (Å)
0.423 0.221
AOne crystal was used for data collection and solving each structure. 
BFigures in parentheses refer to the highest resolution bin.
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A2-SLL. In broad agreement with the structural and alanine scan 
analyses, the affinity-enhanced TCRs, 1G4_α5β100, 1G4_α5β51, and 
1G4_α58β61, showed strong preferences for the native SLL peptide 
sequence at residues W5, T7, Q8, and V9 (Figure 3, A–C). In con-
trast, the TCR mimic 3M4E5 demonstrated a preference for the 
native SLL peptide sequence only at W5, with all other positions 
showing very little amino acid preference (Figure 3, D). Although 
like conformation, the alanine scan profile and MagPix analysis 
revealed lower levels of peptide selectivity compared with the 
affinity-enhanced TCRs. To probe this discrepancy further, we 
developed an approach for the characterization of TCR peptide 
degeneracy using randomized pHLA libraries displayed on phage 
(50). We used this system to identify peptide motif preferences 
for the affinity-enhanced TCRs and TCR mimics that recognized 
Table 2. Structural analyses of TCRs versus TCR mimics binding to pHLA
1G4_α58 β61 TCR MAG-IC3 TCR WT1_α7β2 TCR 3M4E5 Fab Hyb3.3 Fab ESK-1 Fab
Affinity (K
D
) 57 pM 3.8 nM 70 nM 44 nM 18 nM 2000 nM
PDB 2P5E 5BRZ 6RSY 3GJF 1W72 4WUU
Crossing angle (°) 67 58.2 53.8 43.3 40 60.2
ATotal bonds 201 114 178 134 134 183
Pep bonds (bold >10) 4, 5, 6, 7, 8 1, 4, 5, 7, 8 1, 4, 5, 7, 8 4, 5, 6, 7, 8 4, 5, 6, 7, 8, 9 1,4
BHLA >5 bonds (bold >10) B 65, 68, 71,  
72, 73,  
75, 150, 151, 155
66, 154,  
155, 157,  
158, 163
65, 66, 72,  
75, 150, 151,  
154, 155
65, 66, 72,  
150, 155,  
158, 163
65, 69, 72,  
73, 76, 80, 82,  
84, 146, 155
55, 56, 58, 59,  
62, 63, 65, 66,  
155, 162, 167, 169, 170
AHLA bonds 86 98 114 83 100 164
APep bonds 115 (57%) 16 (14%) 64 (36%) 51 (38%) 34 (25%) 19 (10%)
BSA (Å
2
)
 BSA total 2422 2056 2640 2502 2024 2168
 BSA α/H Pep 502 222 308 364 376 186
 BSA β/L Pep 396 320 403 462 90 144
 BSA α/H HLA 674 1020 886 1072 890 636
 BSA β/L HLA 850 494 1043 604 668 1202
ATotal bonds, HLA bond and Pep (peptide) bonds were assessed using a 3.4 Å cutoff for H-bonds and a 4 Å cutoff for vdW. BOnly HLA residues with more 
than 5 bonds are shown. Any peptide or HLA residue with more than 10 contacts is shown in bold. Peptide residue making the most contacts is underlined.
Table 3. MagPix analysis of commonly expressed HLA-A*0201-restricted self-peptides
HLA Antigen Peptide 1G4_α5β100 TCR 1G4_α58β61 TCR 3M4E5_T2 scFv WT1_α7β2 TCR ESK-1 scFv
A2 SLLMWITQC NY-ESO(157–165) 100.0 100.0 100.0 0.0 0.0
A2 RMFPNAPYL WT1(126–134) 0.0 0.0 0.6 100.0 100.0
A2 AIVDKVPSV COPG1(147–155) 0.0 0.0 0.0 0.0 0.0
A2 ALVVQVAEA HEXB(34–42) 0.0 0.0 0.0 0.0 0.1
A2 SLDQPTQTV EIF3C(834–842) 0.0 0.0 0.0 0.0 0.0
A2 GLATDVQTV PSMB3(55–63) 0.0 0.0 0.0 0.0 0.0
A2 ILTDITKGV EEF2(661–669) 0.0 0.0 0.0 0.0 0.0
A2 IMLEALERV SNRPGP15(68–76) 0.0 0.0 0.0 0.0 0.0
A2 VMDSKIVQV KPNA1(434–442) 0.0 0.0 0.1 0.0 0.2
A2 RLQEDPPAGV UBE2A(15–24) 0.0 0.0 0.0 0.0 0.3
A2 KIYEGQVEV RPL5(117–125) 0.0 0.0 0.0 0.0 0.2
A2 NLAENISRV PYGM(271–279) 0.0 0.0 0.0 0.0 0.0
A2 LLDVPTAAV IFI30(16–24) 0.0 0.0 0.0 0.0 0.0
A2 SLSEKTVLL CD59(106–114) 0.0 0.0 0.0 0.0 0.0
A2 ALNEKLVNL EIF3F(349–357) 0.0 0.0 0.0 0.0 0.0
A2 ILDKKVEKV HSP90AB1(570–578) 0.0 0.0 0.1 0.0 0.3
A2 ILDQKINEV ODC1(23–31) 0.0 0.0 0.0 0.0 0.0
A2 VLIDYQRNV XPO1(784–792) 0.0 0.0 0.0 0.0 0.0
A2 GLIEKNIEL DNMT1(425–433) 0.0 0.0 0.0 0.0 0.0
A2 FLDPNNIPKA ALG8(305–314) 0.0 0.0 0.0 0.0 0.0
A2 SLQSTILGV LONP2(51–59) 0.0 0.0 0.2 0.0 0.0
A2 SLYDYNPNL EIF3F(381–389) 0.0 0.0 0.0 0.0 0.0
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W5 was selected by 3M4E5_T2 and 3M4E5_T3, it was not the 
dominant amino acid preference at this position, with phenylala-
nine (F) being preferred by both reagents (Figure 3, E–F). 3M4E5_
T2 and 3M4E5_T3 also displayed very little selectivity in terms 
of amino acid preference at any other position. These findings 
are consistent with the alanine scan results demonstrating that 
the A2-SLL–reactive TCR mimics could tolerate alanine substi-
tutions at any residue outside of the central MW peg in the SLL 
peptide, while the affinity-enhanced TCRs were selective across 
the peptide backbone.
Using this information, we assessed the number of unique 
peptides selected by each reagent to gain insight into their com-
parative crossreactivity. Analysis of next-generation sequencing 
data identified an average of 7068 unique peptides (687,241 total 
reads) for 1G4_α5β51, 4455 unique peptides (689,928 total reads) 
for 1G4_α5β100, and 9012 unique peptides (696,992 total reads) for 
1G4_α58β61. The TCR mimics selected between 3 and 15 times more 
unique peptides compared with the affinity-enhanced TCRs with 
50,765 unique peptides (740,196 total reads) for 3M4E5, 60,699 
unique (692,455 total reads) for 3M4E5_T2, and 32,934 unique 
(727,824 total reads) for 3M4E5_T3. Overall, these data suggest 
that the A2-SLL affinity-enhanced TCRs are less crossreactive (in 
terms of total number of peptides recognized) and less promiscu-
ous in terms of their ability to tolerate amino acid variation across 
the peptide backbone compared with the A2-SLL TCR mimics.
Molecular dynamics simulations reveal peptide selectivity is 
associated with distinctive energetic modes of binding between TCRs 
and TCR-mimic antibodies. Although the structural and alanine 
scan analyses provided useful insights into the recognition mode 
employed by the pHLA-targeting molecules described here, they 
were not fully predictive of the recognition patterns observed in 
the MagPix and randomized pHLA library analysis. For example, 
despite the A2-SLL– and A1-EAD–reactive TCR mimics forming 
seemingly broad peptide contacts, according to the structural 
analysis, and promising alanine scan profiles, these reagents 
bound substantially more self-peptides in the MagPix analysis 
than the affinity-enhanced TCRs. Furthermore, the 
A2-SLL–reactive TCR mimics were characterized by 
more degenerate peptide binding in the randomized 
pHLA library analysis. Consequently, we performed 
molecular dynamics (MD) simulations to extend the 
“snapshot” view available from crystal structures. 
We subjected all 6 structures described in Figure 1 to 
two 500-nanosecond long MD simulations to investi-
gate the biochemical nature and lifetime of contacts 
formed between the peptide and affinity-enhanced 
TCRs or TCR mimics. Interactions were dissected into 
contacts formed between the peptide side chain (ami-
no acid specific) and main chain (conformation specif-
ic) versus time and separated into hydrogen bonding 
(H-bond) and van der Waals (vdW) type interactions. 
In all cases, the affinity-enhanced TCRs made a 
higher number of long-lived contacts with side-chain 
atoms across the peptide compared with main-chain 
interactions (Figure 4, A–C). In contrast, 3M4E5 made 
a lower number of peptide side-chain contacts (Figure 
4D), reflected by a lower overall ratio of peptide side-
chain contacts (H-bond ratio: 0.5, vdW ratio: 2.23) compared with 
the 1G4_α58β61 TCR (H-bond ratio: 1.49, vdW ratio: 5.41) (Supple-
mental Figure 2). Hyb3.3 made virtually no contacts with peptide 
side-chain residues (H-bond ratio: 0.16, vdW ratio: 0.24), focusing 
primarily or exclusively on interactions with the peptide backbone 
(Figure 4E and Supplemental Figure 2). ESK-1 did make peptide 
side-chain interactions, but only with the exposed R1, in line with 
the alanine scan analysis (Figure 4F and Supplemental Figure 2). 
These data suggest that more limited side-chain–mediated recog-
nition patterns, as observed for the TCR mimics, might contribute 
to greater levels of peptide degeneracy.
The energetic landscape of each affinity-enhanced TCR/
TCR mimic-pHLA complex was characterized by calculating their 
binding free energies (using the molecular mechanics Poisson–
Boltzmann surface area [MMPBSA] approach) (51). The MMPBSA 
approach has been used extensively to predict relative protein- 
ligand and protein-protein binding free energies (52, 53). More 
specifically, it has been used to rationalize the effect of muta-
tions on antibody-antigen complexes (54) and the role of a water-
bridged interaction in TCR-pHLA affinity (55) and to predict reli-
able relative binding free energies of pHLA complexes (56). Here, 
we performed 25 × 4 nanosecond MD simulations per complex for 
MMPBSA analysis to ensure reliable and converged results (52, 
56, 57). MMPBSA calculations have the advantage that they can 
be decomposed into per residue contributions to the binding free 
energy, allowing one to predict each residue’s preference toward 
binding. Analysis of the decomposition results demonstrated that 
the affinity-enhanced TCRs were characterized by broad energetic 
signatures, whereby the binding energy was distributed over at 
least 3 peptide residues, with multiple disparate regions driving 
affinity across the HLA surface (Figure 5, A–C, and Supplemen-
tal Figure 3, A–C). On the other hand, the TCR mimics were more 
HLA focused, with 1 or 2 energetic hot spots focused on single 
HLA residues (Figure 5, D–F, and Supplemental Figure 3, D–F). For 
example, although the 1G4_α58β61 TCR made substantial energetic 
interactions with HLA residue R65 (–12 kcal mol–1), this was bal-
Table 4. MagPix analysis of commonly expressed HLA-A*0101–restricted self-
peptides
HLA Antigen Peptide MAG-IC3 TCR Hyb3.3 scFv
A1 EVDPIGHLY MAGE-A3(168–176) 100.0 70.0
A1 EADPTGHSY MAGE-A1(161–169) 0.0 100.0
A1 YSDKYGLGY PLK1(417–425) 0.0 90.7
A1 DTDHYFLRY PIGT(165–173) 0.0 16.8
A1 STDHIPILY GFPT1(218–226) 0.0 0.4
A1 HSDPSILGY GIGYF1(1012–1020) 0.0 15.2
A1 KSDVHLNFY HLTF(499–507) 0.0 0.0
A1 HTDILKEKY DTWD1(262–270) 0.0 0.0
A1 IADMGHLKY PCNA(241–249) 0.0 1.0
A1 LTELPDWSY MRPL52(43–51) 0.0 0.0
A1 ASDPFFRHY GPN2(210–218) 0.0 77.3
A1 ETEKDFSRY AQR(1757–895) 0.0 4.3
A1 GTVYEDLRY UBE2C(71–79) 0.0 0.1
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anced by interactions with multiple peptide residues (W5: –11 kcal 
mol–1, M4: –8 kcal mol–1, Q8: –7 kcal mol–1) and other HLA residues 
(Q155: –6 kcal mol–1). The MAG-IC3 TCR had a balanced energetic 
footprint with important binding contributions from HLA resi-
dues E63, N66, and V158 as well as peptide residues E1, D3, P4, 
and H7 (all around –5 kcal mol–1), and no energetic hot spots were 
detected for the WT1_α7β2 TCR, with most of the binding energy 
being equally balanced over HLA residues R65, R75, and Q155 
and peptide residues P4, N5, and Y8 (all around –6 kcal mol–1). In 
contrast, all of the TCR mimics utilized more focused energetic 
binding to engage their cognate pHLAs. The chief energetic con-
tribution for 3M4E5 was made by HLA residue R65 (–16 kcal 
mol–1), with an additional peptide hot spot at W5 (–7 kcal mol–1). 
Hyb3.3 binding was characterized by strong energetically favor-
able interactions only with HLA residues K146 (–11 kcal mol–1) 
and R65 (–11 kcal mol–1), with the EAD peptide 
playing a minor role. Finally, for ESK-1, energetic 
hot spots were detected at HLA residue K66 (–15 
kcal mol–1) and peptide residue R1 (–13 kcal mol–1), 
with very little contribution from any other pep-
tide residues.
Together with the previous analyses, the MD 
simulations provide further evidence that, rather 
than being driven by the recognition of a domi-
nant amino acid at a single position on the HLA 
or peptide, broad interactions across the peptide 
(particularly with peptide side chains) were asso-
ciated with greater peptide selectivity.
Redirected T cell killing of antigen-positive and 
-negative cell lines using pHLA-targeting bispe-
cifics. On-target versus off-target reactivity of 
affinity-enhanced TCRs and TCR mimics was 
assessed in functional T cell redirection assays 
against antigen-positive and antigen-negative 
cell lines. Cell lines were assessed for RNA tran-
script levels of the genes encoding each protein 
to determine their antigenic status (Supplemen-
tal Figure 4). Soluble bispecific molecules were 
generated by fusing an anti-CD3 scFv (KD = 10 
nM, half-life = 2 minutes) to the β chain of the 
affinity-enhanced 1G4_α58β61 (IMC-1G4_α58β61) 
and MAG-IC3 TCRs (IMC-MAG-IC3) or the 
heavy chain of the TCR mimic scFv 3M4E5_T2 
(3M4E5_T2/anti-CD3), 3M4E5_T3 (3M4E5_T3/
anti-CD3), and Hyb3.3 (Hyb3.3/anti-CD3). 
Reagents recognizing A2-RMF were not included 
because, consistent with evidence from other 
studies (58), we were unable to detect the peptide 
on WT1+ tumor cells by mass spectrometry anal-
ysis (data not shown). IMC-1G4_α58β61 redirected 
T cell killing of A2+NY-ESO+ NCIH-1755 cells was 
approximately 20 times more sensitive when com-
pared with 3M4E5_T2/anti-CD3 and 3M4E5_T3/
anti-CD3, in line with the difference in affinity 
between these reagents (Figure 6A and Supple-
mental Figure 5). No redirected T cell killing of 
A2+NY-ESO– targets was detected for IMC-1G4_
α58β61, whereas 3M4E5_T2/anti-CD3 and 3M4E5_T3/anti-CD3 both 
induced redirected T cell killing of the A2+NY-ESO– antigen-negative 
cell lines HEP-G2, Ren8, and HISMC at EC50s similar to those for 
the A2+NY-ESO-1+ cell line NCIH-1755. Similarly, Hyb3.3/anti-CD3 
demonstrated T cell redirected killing of multiple A1+MAGE-A1– 
antigen-negative cell lines as well as A1+MAGE-A1+ antigen-positive 
cell lines, demonstrating no, or a very small, specificity window. 
In contrast, IMC-MAG-IC3–mediated redirected T cell killing of 
A1+MAGE-A3– antigen-negative cells was absent (HISMC cells) or 
only occurred at very high concentrations (COLO205), demon-
strating a clear specificity window compared with redirected T cell 
killing against A1+MAGE-A3+ antigen-positive cells (Figure 6B and 
Supplemental Figure 6). These findings were confirmed for both 
the A2-SLL and the A1-EAD/EVD reactive reagents in 3 additional 
donors, demonstrating a very similar overall pattern of reactivity 
Figure 2. Alanine scan analysis reveals distinct molecular recognition patterns between 
TCRs and TCR-mimic antibodies. The contribution of peptide side chains to binding speci-
ficity was analyzed using alanine scan mutagenesis (by SPR). Binding affinities of the TCRs 
and TCR-mimic antibodies were determined using single-cycle kinetic analysis. Bar graphs 
show binding affinity as a percentage relative to the binding affinity to the index peptide. (A) 
A2-SLL affinity-enhanced TCRs, (B) A2-SLL TCR mimics, (C) A1-EVD affinity-enhanced TCRs, 
(D) Hyb3.3, (E) A2-RMF affinity-enhanced TCRs, and (F) ESK-1. Representative data from 3 
independent experiments are shown.
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Figure 3. Deep sequencing of peptides from randomized pHLA phage libraries demonstrates the binding degeneracy of pHLA-targeting reagents. 
Sequence logos (iceLogo software) and heatmaps were generated from NGS sequencing of pan 3 data identifying the distribution of amino acid identities 
per position of the peptide selected by A2-SLL–reactive affinity-enhanced TCRs and TCR-mimic antibodies. The abundance of an amino acid is shown 
by intensity of color. Outlined boxes identify the amino acids of the cognate antigen SLL. Data are shown as the average of 2 experimental repeats. (A) 
1G4_α5β100, (B) 1G4_α5β51, (C) 1G4_α58β61, (D) 3M4E5, (E) 3M4E5_T2, and (F) 3M4E5_T3.
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this indicates that the mode of T cell activation is not affected by 
the selectivity of these bispecifics during T cell redirection. Fur-
thermore, we observed no cytokine release for IMC-1G4_α58β61 in 
response to A2+NY-ESO– targets, while for 3M4E5_T3/anti-CD3, 
responses to A2+NY-ESO– targets were observed for virtually all 
cytokines tested. This target-independent activation may also 
explain why 3M4E5_T3/anti-CD3 induced greater cytokine release 
against the A2+NY-ESO+ targets compared with IMC-1G4_α58β61, as 
responses to antigens other than A2-SLL for 3M4E5_T3/anti-CD3 
may have resulted in an increase in target abundance for this reagent.
Overall, the HLA-targeting bispecifics based on the natural 
TCR scaffold retained higher levels of specificity in cellular test-
ing, consistent with the MagPix and randomized pHLA library 
(Supplemental Figure 4). Finally, we explored whether ImmTAC 
molecules might generate a different activation signal in CD8+ and 
CD4+ T cells compared with the TCR-mimic antibodies. Purified 
CD8+ or CD4+ T cells from a healthy donor were redirected against 
A2+NY-ESO+ and A2+NY-ESO– target cells using either IMC-1G4_
α58β61 or 3M4E5_T3/anti-CD3, and the production of cytokines 
was measured using a Human TH1/TH2 10-Plex Tissue Culture 
Kit (Supplemental Figure 7). Overall, the cytokine profiles for both 
reagents were consistent with an IFN-γ–driven Th1 CD4+ T cell and 
effector CD8+ T cell response, while all other cytokines tested were 
only detectable at very low levels. We previously reported a similar 
pattern of activation for CD8+ and CD4+ T cells upon redirection 
with ImmTAC molecules (59), and together with these findings, 
Figure 4. Molecular dynamics 
simulations reveal broad side-
chain contacts with the pep-
tide drive specificity. Relative 
number of H-bonds and vdW 
interactions formed between 
either the main or side chain 
of each peptide residue to 
the TCR/TCR mimic over the 
course of our MD simulations. 
Total side- versus main-chain 
ratios for H-bonds and vdW 
interactions are shown, with 
the larger value (side or main 
for each category) scaled to 
100% (absolute values for 
all contacts are provided in 
Supplemental Figure 2). MD 
simulations were performed 
using independent (random 
velocity vectors assigned 
upon heating) 500 ns long 
MD simulations for each 
structure. (A) 1G4_α58β61-A2-
SLL, (B) MAG-IC3-A1-EVD, (C) 
WT1_α7β2-A2-RMF, (D) 3M4E5-
A2-SLL, (E) Hyb3.3-A1-EAD, (F) 
ESK-1-A2-RMF.
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strated exquisite specificity, as evidenced by absence of T cell redi-
rection against 10 A2+NY-BR-1– antigen-negative cell lines, even at 
high concentrations (up to 2 nM of IMC-NYBR1 for a KD = 47 pM 
affinity reagent) (Figure 7A). We solved the structure of the NYBR1-
A2-SLS complex at 2.3 Å resolution (Table 1), which demonstrated 
that NYBR1 bound canonically, with a normal crossing angle (63.6°) 
and a BSA slightly above the reported range (2835Å2), engaging 
with 7 of the 9 peptide residues (32% peptide contacts) (Supplemen-
tal Figure 8A). This binding mode enabled fine specificity across the 
peptide, evidenced by sensitivity to alanine substitutions at every 
peptide position apart from peptide position 1 (Figure 7B). Analy-
sis of contacts and energetics from MD simulations demonstrated 
a highly peptide side-chain–mediated interaction (Supplemental 
Figure 8, B–D), with important contributions from 6 of the 9 resi-
dues in the SLS peptide. Although there was a slight energetic focus 
analyses. These findings support the hypothesis that dispersed 
peptide contacts with the comparatively broad peptide side-
chain–focused energetic signature are predictive of the ability to 
discriminate between different peptides.
The NYBR1 TCR exhibits no cellular off-target reactivity and 
utilizes a broad, peptide side-chain–centric binding mode. In order 
to test the notion that peptide selectivity is associated with broad 
contacts with peptide side chains and a dispersed energetic profile, 
we extended our analysis to include an affinity-enhanced TCR that 
was known to be highly selective for its target pHLA. The NYBR1 
TCR was affinity matured against a cancer-specific HLA-A*02:01 
restricted peptide (SLSKILDTV; herein referred to as SLS peptide) 
derived from the NY-BR-1 lineage antigen and used to generate an 
ImmTAC molecule (IMC-NYBR1). In cellular testing, as assessed 
by both IFN-γ release and target cell killing, IMC-NYBR1 demon-
Figure 5. Binding free energy decom-
position analysis of TCR and TCR 
mimic–pHLA interactions. Per residue 
decomposition of the binding free 
energy obtained from our MMPBSA 
calculations to identify energetic 
hot spots for each TCR or TCR mimic 
interaction with cognate pHLA. A top-
down view of each pHLA is shown, with 
the peptide depicted as sticks and the 
HLA as a surface. Color mapping of the 
decomposition results for each residue 
was performed across the entire binding 
interface and used to indicate which res-
idues across this interface favor (blue) 
or disfavor (red) binding (with white 
indicating no preference). Bar graphs for 
all decomposition results are provided in 
Supplemental Figure 3. MD simulations 
were performed using 25 independent 
(random velocity vectors assigned upon 
heating) 4 ns long MD simulations for 
each structure. (A) 1G4_α58β61-A2-SLL, (B) 
MAG-IC3-A1-EVD, (C) WT1_α7β2-A2-RMF, 
(D) 3M4E5-A2-SLL, (E) Hyb3.3-A1-EAD, 
(F) ESK-1-A2-RMF.
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HLA coengagement by the T cell coreceptors CD8 and CD4, 
removal of which in CD8/CD4 coreceptor knockout mice has been 
shown to enable the selection of T cells with TCRs that can bind 
to non-MHC proteins, such as CD155 (61, 62). A number of recent 
reports have also suggested that, probably as a consequence of thy-
mic selection, TCRs have coevolved to recognize pHLA (63–65). 
This “coevolution” model is consistent with findings from a recent 
study revealing that TCRs have a unique variable domain orienta-
tion compared with antibodies, the absence of which might restrict 
antibodies from reproducing the natural ability of TCRs to dis-
criminate between different HLA-presented peptides (66). Thus, 
TCRs have multiple unique selection mechanisms and structural 
features that guide pHLA recognition. We have previously demon-
strated that affinity-enhanced TCRs maintain many of the binding 
characteristics of their thymically selected WT progenitors, with 
stronger binding generally being driven through the formation of 
new interactions with both the peptide and HLA surface (13, 44, 45, 
67–69). This feature likely provides an advantage for generating 
affinity-enhanced TCRs with the ability to retain a similar specific-
ity profile compared with natural, thymically selected TCRs.
The literature indicates that T cell potency is tuned by a TCR 
affinity threshold that is optimal in the low micromolar to high 
nanomolar range (17, 34, 70–74). For soluble bispecific reagents, 
this affinity threshold is controlled at the effector end of the mol-
toward HLA residue Q155 (–6 kcal mol–1) and peptide residue K4 (–9 
kcal mol–1), a number of energetic contributions were made across 
the entire HLA surface and peptide. Thus, consistent with our other 
observations in this study, the fine specificity of the NYBR1 TCR 
was associated with a broad energetic binding mode characterized 
by interactions with multiple peptide side chains.
Discussion
The identification of cancer-specific targets for solid tumors is 
challenging because cell-surface antigens are often expressed on 
a wide range of tissues. Molecules such as CD19 and others have 
proved effective targets for liquid tumors because on-target toxicity 
is limited to mainly hematopoietic cells that can repopulate from 
the bone marrow following treatment (60). Another key source of 
antigens is dysregulated or mutated intracellular proteins. Howev-
er, many of these proteins are only presented on the cell surface in 
the context of pHLA. It is interesting to note that, even in response 
to very common human pathogens (i.e., influenza), natural anti-
bodies recognizing pHLA have not been detected, suggesting that 
humoral responses to pHLA are either ineffective or dangerous to 
the host. Unlike antibodies, TCRs are selected to recognize pHLA 
in the thymus, which deletes T cells with TCRs that bind strongly 
to self-pHLA (and presumably removes TCRs that bind in a pep-
tide-independent manner). This process is controlled in part by 
Figure 6. Redirected T cell killing of antigen-positive and -negative cell lines using pHLA-targeting bispecifics. The activity of the ImmTAC molecules 
and the TCR mimic/anti-CD3 fusions was tested against a range of antigen-positive and antigen-negative cell lines (tumor and healthy cells) using 
IncuCyte killing assays. PBMCs from 1 healthy donor are shown. PBMCs from an additional 3 healthy donors were used to repeat the assay (Supplemental 
Figure 4). Data are plotted using area under the curve analysis. Error bars show SD from 3 experimental repeats. (A) IMC-1G4_α58β61, 3M4E5_T2/anti-CD3, 
and 3M4E5_T3/anti-CD3 T cell redirection against HLA-A*02:01+NY-ESO-1+ (NCI-H1755) and HLA-A*02:01+NY-ESO-1– (HEP-G2, Ren8, and HISMC) cells lines. 
(B) IMC-MAG-IC3 and Hyb3.3/anti-CD3 T cell redirection against HLA-A*01:01+MAGE-A3+ (HCC1428 and NCI-H1703), HLA-A*01:01+MAGE-A1+ (HCC1428 and 
NCI-H1703), and HLA-A*01:01+MAGE– (COLO205 and HISMC) cells lines.
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that 3M4E5 bound via 2 main hot spots: 1 on peptide residue 
W5 and 1 on HLA residue R65. These findings were mirrored 
in the randomized pHLA library analysis that demonstrated 
the A2-SLL–reactive TCR mimics were all more degenerate (in 
terms of amino acid preferences across the peptide backbone) 
as compared with the A2-SLL–reactive affinity-enhanced TCRs 
and were predicted to select a far larger number of unique pep-
tide sequences. Interestingly, this hot spot–mediated binding 
mode has also been observed for some natural TCRs, but has 
been shown to correlate with high levels of TCR crossreactivity 
and has been implicated in autoimmunity (49, 75). The ESK-1 and 
Hyb3.3 TCR mimics also employed hot spot–binding modes, espe-
cially focused toward residues on the HLA surface, and demon-
strated loss of peptide selectivity in biochemical (ESK-1 and Hyb3.3) 
and cellular (Hyb3.3) testing. In contrast, the TCR-based reagents 
tested all exhibited superior peptide selectivity in biochemical 
and cellular tests and were characterized by binding modes that 
included a greater combination of balanced energetic interactions 
across the peptide and HLA surfaces. This was exemplified by the 
NYBR1 TCR (by far the cleanest molecule tested in both the molec-
ular and cellular analysis), which also demonstrated a broad ener-
getic binding mode, with the majority of peptide contacts through 
side-chain interactions. Although the TCR mimics selected in this 
study were generated using a different approach from the affinity- 
enhanced TCRs, our data suggest that the reagents based on the 
natural TCR scaffold were better able to discriminate between dif-
ferent peptides by utilizing peptide-specific binding interactions.
Even though we focused on 3 published TCR-mimic antibodies 
because of available structures (25, 31, 36), our data also have impli-
ecule, while the affinity of the pHLA targeting end must be opti-
mized to achieve potency according to receptor occupancy. For 
most tumor-associated pHLAs, their natural presentation levels 
can be very low (often below 10 copies of each specific peptide 
epitope per cell) (3, 33). Consequently, binding in the femto- to 
picomolar affinity range is needed to achieve a therapeutically 
relevant receptor occupancy level: a feat that has been achieved 
for monovalent TCR-based bispecifics (22, 24). The literature, 
together with the data presented here, suggests that, with current 
technologies, engineering a TCR-mimic antibody to achieve this 
affinity range while maintaining peptide selectivity is more chal-
lenging (32). Some soluble TCR mimics have been designed as full 
antibodies, thus achieving much stronger binding through avidity 
effects (38). However, this essentially halves the number of effec-
tor molecules per target cell, a major issue if antigen presentation 
levels are already limiting.
Here, we interrogated the molecular basis of pHLA recogni-
tion of a panel of T cell–redirecting bispecifics using a combina-
tion of structural, biochemical, and computational approaches. 
All the affinity-enhanced TCRs utilized a canonical native TCR-
like binding mode, maintaining broad contacts across the peptide 
backbone. This finding likely represents the advantage of using 
reagents that have been developed from a thymically selected 
TCR progenitor. Our data also reveal that a native-like binding 
mode is necessary, but not sufficient, for enabling peptide selec-
tivity. For instance, despite the 3M4E5 TCR mimic binding in an 
almost identical fashion to a native TCR, with peptide contacts 
across the peptide backbone, it still performed poorly in cellular 
crossreactivity assays. Our MD simulation analysis demonstrated 
Figure 7. The NYBR1 TCR exhibits no cellular off-target reactivity and is sensitive to alanine substitutions across the peptide backbone. (A) The activity 
of IMC-NYBR1 was tested against a range of HLA-A*02:01+NYBR1+ (CAMA1 and CAMA1 β2m) and HLA-A*02:01
+NYBR1– cell lines (MDA-MB-231, HA13, 
HAo14, HDMEC2, Ren8, CM12 HCC1419, NCI-H661, SNU475, and SNU398) using IFN-γ ELISpot (bar graphs) and IncuCyte killing assays (area under the curve 
analysis) in 2 donors. Error bars show SD from 3 experimental repeats. (B) The contribution of peptide side chains to binding specificity was analyzed using 
alanine scan mutagenesis (by surface plasmon resonance). Binding affinities of the NYBR1-A2-SLS interaction were determined using single-cycle kinetic 
analysis. Bar graphs show binding affinity as a percentage relative to the binding affinity to the index peptide.
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TCR constructs for biophysical analysis were designed to include the 
variable and constant domains of both chains (α and β) with an engi-
neered interchain disulphide bond (23). Antibody reagents for bio-
physical analysis were generated as scFv with a linker between the vari-
able heavy and light chains (the constant domains were not included 
in the construct). Hyb3.3 scFv expression cassette was cloned into 
pCEP4 and protein expressed in mammalian cells using the ExpiCHO 
Expression System (Thermo Fisher Scientific), as it did not express in 
E. coli. TCR constructs for T cell redirection experiments were gener-
ated with an anti-CD3 scFv fused to the TCR-β chain (ImmTAC mol-
ecules, total size ~75 kDa) (22). TCR-mimic antibody constructs for T 
cell redirection experiments were designed as scFv with an anti-CD3 
scFv fused to the heavy chain (total size ~50kDa).
Analysis of on-target and off-target T cell reactivity via redirec-
tion using anti-pHLA/anti-CD3 bispecific reagents. The activity of the 
ImmTAC molecules (TCR-CD3 scFv fusions) and the TCR mimic 
scFv-CD3 scFv fusions was tested through their ability to redirect T 
cells against a range of antigen-positive and antigen-negative cell lines 
(tumor and healthy cells). IncuCyte killing assays were performed 
according to the manufacturer’s instructions (Sartorius). For multiplex 
cytokine analysis, healthy donor CD4+ and CD8+ T cells were isolated 
by magnetic separation using negative selection kits following the 
manufacturer’s instructions (Miltenyi).
MagPix peptide screening. Affinity-enhanced TCRs and TCR 
mimic scFvs were subjected to peptide crossreactivity analysis 
using a MagPlex bead kit (Invitrogen). Several common peptides 
expressed by healthy cells were refolded with either biotin-tagged 
HLA-A*02:01 or biotin-tagged HLA-A*01:01 (detailed in Tables 3 
and 4). Phagemid-encoded TCRs/TCR mimics were expressed on 
the surface of bacteriophage M13, fused to capsid protein pIII (81), 
and binding to biotinylated self-peptide–HLA complexes attached to 
neutravidin-conjugated MagPlex magnetic beads assayed. Positive-
ly bound beads were identified by MagPix analysis using a phage- 
specific PE-conjugated anti-M13 bacteriophage coat protein g8p 
antibody (RL-ph2, 2B Scientific Limited, MUB0604) conjugated to 
R-phycoerythrin using a Conjugation Kit (Abcam, ab102918). Pep-
tides generating a signal above background (3 times median intensity 
of all bead regions bound to native helper phage) were classified 
as positive binders and binding expressed as a percentage of signal 
obtained relative to index peptide. Averages of triplicate measure-
ments for each interaction were determined within each experiment, 
and percentage binding for each interaction is reported as the aver-
age of several experimental repeats.
SPR single-cycle kinetic analysis. Purified TCRs and TCR mimic 
scFvs were subjected to SPR analysis using a BIAcore3000 with single- 
cycle kinetic analysis, as previously reported (67, 69).
Panning using scHLA libraries. scHLA libraries were generated 
as previously described (50). Biotinylated affinity-enhanced TCRs 
(1G4_α5β100, 1G4_α5β51, and 1G4_α58β61) and TCR-mimic antibodies 
(3M4E5, 3M4E5_T2, and 3M4E5_T3) were captured on streptavidin- 
coated paramagnetic beads and incubated with the library of purified 
phage particles preblocked in 3% MPBS buffer. Phage particles were 
eluted in trypsin and used to infect early log phase TGI E. coli cells 
and plated onto YTEag plates at 30°C for 16 hours. Three rounds of 
selection were performed.
Deep sequencing of pHLA libraries. DNA was isolated from each 
glycerol stock by Miniprep (Zymoprep II Kit, Zymo Research). 
cations for other published studies of TCR mimics. For instance, the 
TCR mimic ESK-1 has been shown to target the Wilms tumor anti-
gen in mouse models (29, 38), despite evidence demonstrating that 
the A2-RMF antigen is not expressed (58). This finding, combined 
with the data shown here, suggests that the activities reported for 
ESK-1 may be mediated by recognition of another peptide or in a 
peptide-independent fashion. Although it is clear that engineering 
pHLA selectivity is still one of the major challenges for TCR mim-
ics (76), there are emerging reagents that exhibit more promising 
specificity profiles, including reagents targeting an HLA-A*02:01 
restricted EBV LMP2A426–434 (CLGGLLTMV) epitope (77) and an 
α-fetoprotein158–166 (FMNKFIYEI) epitope (78), the second of which 
has entered clinical trials as a CAR for the treatment of liver cancer. 
Our data demonstrate the importance of robust specificity testing 
of pHLA-targeting molecules, in line with our own preclinical safety 
testing package (79), that should be considered for the development 
of soluble pHLA-targeting bispecifics.
In summary, we demonstrate that by combining structural 
and biochemical data with atomistic MD simulations, the inter-
actions underpinning pHLA recognition can be dissected in detail 
and can be used to better understand the specificity of pHLA- 
targeting reagents. Although these findings need to be further val-
idated using in vivo tumor models, they extend our understand-
ing of the molecular rules that determine selective recognition of 
pHLA and shed additional light on how TCRs engage pHLA in a 
peptide-dependent fashion. Finally, these observations also high-
light the challenges associated with engineering pHLA-targeting 
molecules that can truly mimic TCR-like specificity.
Methods
Cell lines. COLO205, HCC1428, NCI-H1703, NCI-H1755, 
NCI-H1944, NCI-H2087, NCI-H441, and T2 antigen-presenting 
cells (LCL721 × CEM-C7) were purchased from ATCC and cultured 
in RPMI supplemented with 10% FCS, 2 mM l-glutamine, and 1% 
(v/v) penicillin/streptomycin. HEP-G2 cells were purchased from 
ATCC and cultured in EMEM supplemented with 10% FCS. HISMC 
and HREpic8 (Ren8) cells were purchased from ScienCell and cul-
tured in smooth muscle cell medium or epithelial cell medium, 
respectively. Cell line authentication and mycoplasma testing were 
routinely carried out by the LGC Standards Cell Line Authentication 
Service (www.lgcstandards.com) and Mycoplasma Experience Ltd. 
(www.mycoplasma-exp.com), respectively.
TCR engineering. To obtain TCRs with affinity enhanced for 
HLA-A*02:01 SLLMWITQC (NY-ESO-1157–165), HLA-A*01:01 EVDPIGH-
LY (MAGE-A3161–134), and HLA-A*02:01 RMFPNAPYL (WT-1126–134), the 
WT 1G4, MAGE-A3, and WT1 TCRs were subjected to phage display, as 
previously described (24). A panel of high-affinity TCRs were obtained 
with mutations in the α and/or the β chain (data not shown). TCRs from 
these panels were selected for this study according to their similarity in 
affinity to available TCR-mimic antibodies. Additionally, some stronger 
affinity-engineered TCRs were selected according to the availability of 
corresponding TCR-pHLA complex structures to enable direct structural 
comparisons with the TCR-mimic antibodies.
Construct design, protein expression, and purification. The modified 
TCRs, the TCR mimics, β2m, and the HLA-A*01:01, and HLA-A*02:01 
heavy chains were cloned into the pGMT7 vector and expressed in the 
BL21 (DE3) Rosetta pLysS E.coli strain as described previously (16, 80). 
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added as necessary to neutralize the total system charge. The ff14SB 
(88) and TIP3P (89) force fields were used to describe protein and 
water molecules, respectively. Following minimization, heating, and 
equilibration (see Supplemental Methods section Structure equili-
bration procedure), each system was subjected to two 500 ns long 
production MD simulations (random velocity vectors assigned upon 
heating) in the NPT ensemble (1 atm, 298 K). Production MD simu-
lations were run with the SHAKE algorithm applied, a 2 fs time step, 
and a collision frequency of 1 ps−1. An 8 Å direct space nonbonded 
cutoff was applied with long-range electrostatics evaluated using 
the particle mesh Ewald algorithm (90). H-bond (including water 
bridged hydrogen bonds) and vdW interactions were evaluated from 
snapshots saved every 10 ps, using the last 450 ns of each trajectory 
(900 ns per TCR/Fab-pHLA). An H-bond was defined as on if the 
donor acceptor distance was within 3.0 Å and the donor hydrogen 
acceptor angle was within 45° to 180°. A vdW interaction was defined 
as on if 2 heavy atoms were within 4 Å of one another.
Statistics. Detailed methodology is described in the Structure 
equilibration procedure section of Supplemental Methods.
Study approval. PBMCs were obtained from healthy volunteers. 
The Oxford A REC–approved protocol 13/SC/0226 was used to obtain 
written consent for all blood donations and was fully approved by the 
National Research Ethics Committee South Central.
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Sequencing libraries were prepared with molecular indexing based on 
a method described previously (82). Libraries were sequenced using 
Illumina V3 SBS chemistry on the MiSeq sequencer. Basecalling and 
sample demultiplexing were performed using MiSeq reporter to gen-
erate fastq files and were processed with custom analysis pipeline. 
Peptide repertoire analysis was performed using Excel, and sequence 
logos were generated using iceLogo standalone tool (83). Sequence 
clustering analysis was performed with GibbsCluster, version 2.0, web 
server using default settings (84).
X-ray crystallography. Crystals were grown at 18°C by vapor dif-
fusion via the sitting drop technique. All crystallization screening and 
optimization experiments were completed with an Art Robbins Phoe-
nix Dispensing Robot (Alpha Biotech Ltd.). 200 nL of 10 to 15 mg/mL 
TCR-pHLA complex mixed at a 1:1 molar ratio was added to 200 nL 
of reservoir solution. INTELLI-PLATES were then sealed and incu-
bated in a crystallization incubator at 18°C (RuMed, Rubarth Apperate 
GmbH) and analyzed for crystal formation using a Rock Imager 2 (For-
mulatrix). Crystals selected for further analysis were cryoprotected 
with ethylene glycol to 25% and then flash-cooled in liquid nitrogen in 
Litho loops (Molecular Dimensions). For WT1_α7β2-A2-RMF, optimal 
crystals were obtained in 0.1 M HEPES pH 7, 0.1M ammonium, 20% 
v/v Sok-CP7. For NYBR1-A2-SLS, optimal crystals were obtained in 
Pact premier (Molecular Dimensions) condition B07 (0.2 M sodium 
chloride, pH 6.0, 0.1 M MES, and 20% PEG 6000). Diffraction data 
were collected at several different beamlines at the Diamond Light 
Source using a Dectris Pilatus 6M detector. Using the rotation meth-
od, 1000 frames were recorded, each covering 0.2° of rotation. Reflec-
tion intensities were estimated with the XIA2 package (45, 46), and 
the data were scaled, reduced, and analyzed with AIMLESS and the 
CCP4 package (47). TCR/pHLA complex structures were solved with 
molecular replacement using Phaser (49), using PDB 4I4W as a start-
ing model for pHLA and PDB 3O4L as a starting model for NYBR1 
TCR. Accession code for the crystal structures reported in this study 
have been uploaded to the RCSB’s Protein Data Bank database (PDB 
WT1_α7β2-A2-RMF: 6RSY and NYBR1-A2-SLS: 6R2L).
MD simulations and MMPBSA calculations. Periodic bound-
ary simulations and MMPBSA calculations were performed with 
the Amber16 suite of programs (85). X-ray crystal structures of the 
7 TCR/Fab-pHLA complexes investigated were used as the start-
ing points for MD simulations. Missing residues were added using 
Modeller, version 9 (86). MolProbity was used to modify histidine 
tautomerization states (tautomerization states used can be found in 
Supplemental Table 2) and Asn/Gln side-chain orientations under 
the criteria of optimizing the internal H-bond network. PropKa, ver-
sion 3.0 (87), was used to check the likely protonation states of all 
titratable residues for pH 7 (all residues were modeled in their stan-
dard protonation states). Each system was solvated in a rectangular 
box of water (with all crystallographic waters retained) extending at 
least 10 Å away from any protein atom. Sodium or chloride ions were 
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